Early Use of Oral Semaglutide in the UK: a Cost-Effectiveness Analysis Versus Continuing Metformin and SGLT-2 Inhibitor Therapy
Source : https://bmjopen.bmj.com/content/13/9/e070473
Objectives Many people with type 2 diabetes experience clinical inertia, remaining in poor glycaemic control on oral glucose-lowering medications rather than intensifying treatment with a glucagon-like peptide-1 receptor agonist, despite...
Many people with type 2 diabetes experience clinical inertia, remaining in poor glycaemic control on oral glucose-lowering medications rather than intensifying treatment with a glucagon-like peptide-1 receptor agonist, despite an efficacious, orally administered option, oral semaglutide, being available. The present study evaluated the...
Share
Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs
Source : https://pubmed.ncbi.nlm.nih.gov/37762862/
In spite of the widespread use of lifestyle modifications programs, many patients with PCOS are obese and prevalence of obesity in PCOS remains high. In this study, we present the...
In conclusion, treatment with semaglutide, at low doses, significantly reduces body weight in almost 80% of obese PCOS patients who were unresponsive to a previous lifestyle plan. It is often associated with the normalization of menstrual cycles, and these important results are obtained with very few side effects.
Share
Positive additive interaction effects of age, sex, obesity, and metabolic syndrome on left ventricular dysfunction - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37743094/
The MetS is independently associated with LVDD and impaired GLS. From the public health implications, prevention of MetS in women, elderly, and obese individuals might result in a greater reduction...
The MetS is independently associated with LVDD and impaired GLS. From the public health implications, prevention of MetS in women, elderly, and obese individuals might result in a greater reduction of LVDD and LVSD risk in cardiovascular high-risk population.
Share
Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting - Endocrine
Source : https://link.springer.com/article/10.1007/s12020-023-03534-0
Background Obesity is defined as excess adipose tissue causing a deterioration in health, but diagnosing the causes and deciding on treatment can be challenging. Several randomized controlled clinical trials (RCT)...
Injectable semaglutide in a real-world setting resulted in similar weight loss and had a similar side effect profile as was observed in randomized controlled trials.
Share
Case Report: Semaglutide-associated depression: a report of two cases
Source : https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1238353/full
Semaglutide, as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was approved for glucose control in type 2 diabetes mellitus in 2017 and approved for weight loss in 2021 by the...
Conclusions/Relevance: Depression was improved or relieved after discontinuation of semaglutide in both cases. Possible psychiatric adverse effects of depression should be taken into consideration when semaglutide is administered to patients.
Share